Literature DB >> 18839270

Cyclosporin A treatment for Japanese patients with severe adult-onset Still's disease.

Mio Mitamura1, Yoshifumi Tada, Syuichi Koarada, Hisako Inoue, Rie Suematsu, Akihide Ohta, Kohei Nagasawa.   

Abstract

For over 10 years there have been no clinical studies about adult-onset Still's disease (AOSD) in Japan. We aimed to investigate recent clinical features and treatment of AOSD and to evaluate the efficacy of cyclosporin A (CyA) in the treatment of AOSD. The data from 34 patients with AOSD who were admitted to our hospital between 1994 and 2007 were analyzed retrospectively. Of several immunosuppressive agents, the efficacy of CyA given to seven patients was precisely evaluated. Clinical features observed in this study did not differ from those in our previous study, and serum ferritin levels were elevated in all the patients. Among immunosuppressive agents CyA, used concomitantly with corticosteroids (CS) for seven patients with severe AOSD, proved to be very effective. The disease was led to remission promptly by CyA in six patients, and all the patients except one experienced no recurrence. These results suggest that CyA can be one of the potent candidates to be used next to CS for patients with AOSD that is resistant to CS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839270     DOI: 10.1007/s10165-008-0126-0

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  7 in total

Review 1.  Treatment of adult-onset Still's disease: a review.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Thomas Henry; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2014-12-22       Impact factor: 2.423

Review 2.  Adult-Onset Still's Disease: Still a Serious Health Problem (a Case Report and Literature Review).

Authors:  Mojgan Agha-Abbaslou; Ana Maria Bensaci; Oluchi Dike; Mark C Poznansky; Arooj Hyat
Journal:  Am J Case Rep       Date:  2017-02-03

3.  Adding colchicine to immunosuppressive treatments; a potential option for biologics-refractory adult-onset Still's disease.

Authors:  Tomoyuki Asano; Makiko Yashiro Furuya; Shuzo Sato; Hiroko Kobayashi; Hiroshi Watanabe; Eiji Suzuki; Kiyoshi Migita
Journal:  BMC Res Notes       Date:  2018-05-21

Review 4.  Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.

Authors:  Meng-Yan Wang; Jin-Chao Jia; Cheng-De Yang; Qiong-Yi Hu
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

5.  Adult-onset Still's disease evolving with multiple organ failure and death: A case report and review of the literature.

Authors:  Zhong-Bin Han; Ju Wu; Jing Liu; He-Ming Li; Kai Guo; Tong Sun
Journal:  World J Clin Cases       Date:  2021-02-06       Impact factor: 1.337

Review 6.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

7.  Severe Adult-onset Still Disease with Constrictive Pericarditis and Pleuritis That Was Successfully Treated with Tocilizumab in Addition to Corticosteroids and Cyclosporin A.

Authors:  Hoshimi Kawaguchi; Hiroto Tsuboi; Mizuki Yagishita; Toshihiko Terasaki; Mayu Terasaki; Masaru Shimizu; Fumika Honda; Ayako Ohyama; Hiroyuki Takahashi; Haruka Miki; Masahiro Yokosawa; Hiromitsu Asashima; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.